NOAC-Based Sual Therapy Versus Warfarin-Based Triple Therapy After Percutaneous Coronary Intervention or Acute Coronary Syndrome in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis
Dahal K, Mosleh W, Almnajam M, Khaddr M, Adeel M, Vashist A, Robinson P, Azrin M, Lee J. NOAC-Based Sual Therapy Versus Warfarin-Based Triple Therapy After Percutaneous Coronary Intervention or Acute Coronary Syndrome in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis. Cardiovascular Revascularization Medicine 2020, 21: 1202-1208. PMID: 32173329, DOI: 10.1016/j.carrev.2020.03.012.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAnticoagulantsAtrial FibrillationDrug Therapy, CombinationFibrinolytic AgentsHumansPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsWarfarinConceptsAcute coronary syndromePercutaneous coronary interventionRandomized clinical trialsDual therapyTriple therapyStent thrombosisAtrial fibrillationCoronary syndromeCoronary interventionSystematic reviewRelevant non-major bleedingRisk of STComposite of mortalityConcomitant atrial fibrillationEfficacy of NOACsMajor efficacy outcomeNon-major bleedingTIMI minor bleedingDual antiplatelet therapyPrimary safety outcomeBleeding outcomesCRNM bleedingIschemic outcomesISTH majorP2Y12 agents